These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 18679646)

  • 1. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
    Ohlmann CH; Markert E; Gerharz M; Pfister D; Dienes HP; Engelmann U; Heidenreich A
    Urologe A; 2008 Sep; 47(9):1218-23. PubMed ID: 18679646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
    J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
    Guérin O; Formento P; Lo Nigro C; Hofman P; Fischel JL; Etienne-Grimaldi MC; Merlano M; Ferrero JM; Milano G
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):51-7. PubMed ID: 17593391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases.
    Mathew P; Wen S; Morita S; Thall PF
    J Interferon Cytokine Res; 2011 Jul; 31(7):539-44. PubMed ID: 21323568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
    Tsao AS; Liu S; Fujimoto J; Wistuba II; Lee JJ; Marom EM; Charnsangavej C; Fossella FV; Tran HT; Blumenschein GR; Papadimitrakopoulou V; Kies MS; Hong WK; Stewart DJ
    J Thorac Oncol; 2011 Dec; 6(12):2104-11. PubMed ID: 21892101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Promising new treatment options for metastatic androgen-independent prostate cancer].
    Tan W
    Actas Urol Esp; 2007 Jun; 31(6):680-5. PubMed ID: 17896565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.
    Beer TM; Garzotto M; Henner WD; Eilers KM; Wersinger EM
    Br J Cancer; 2004 Oct; 91(8):1425-7. PubMed ID: 15467765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer.
    Mathew P; Fidler IJ; Logothetis CJ
    Semin Oncol; 2004 Apr; 31(2 Suppl 6):24-9. PubMed ID: 15176001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
    Cathomas R; Rothermundt C; Klingbiel D; Bubendorf L; Jaggi R; Betticher DC; Brauchli P; Cotting D; Droege C; Winterhalder R; Siciliano D; Berthold DR; Pless M; Schiess R; von Moos R; Gillessen S;
    Clin Cancer Res; 2012 Nov; 18(21):6049-57. PubMed ID: 22977195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
    Gross M; Higano C; Pantuck A; Castellanos O; Green E; Nguyen K; Agus DB
    BMC Cancer; 2007 Jul; 7():142. PubMed ID: 17662137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer MJ
    Intern Med J; 2005 Aug; 35(8):468-72. PubMed ID: 16176469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.
    Small EJ; Bok R; Reese DM; Sudilovsky D; Frohlich M
    Semin Oncol; 2001 Aug; 28(4 Suppl 15):71-6. PubMed ID: 11685733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
    Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
    Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
    Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.
    Mathew P; Pisters LL; Wood CG; Papadopoulos JN; Williams DL; Thall PF; Wen S; Horne E; Oborn CJ; Langley R; Fidler IJ; Pettaway CA
    J Urol; 2009 Jan; 181(1):81-7; discussion 87. PubMed ID: 19012911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Hofer MD; Rubin MA
    J Clin Oncol; 2005 Feb; 23(6):1332-3; author reply 1333-4. PubMed ID: 15718346
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase I/II study of weekly docetaxel and vinblastine in the treatment of metastatic hormone-refractory prostate carcinoma.
    Tester W; Ackler J; Tijani L; Leighton J
    Cancer J; 2006; 12(4):299-304. PubMed ID: 16925974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
    Tzelepi V; Efstathiou E; Wen S; Troncoso P; Karlou M; Pettaway CA; Pisters LL; Hoang A; Logothetis CJ; Pagliaro LC
    J Clin Oncol; 2011 Jun; 29(18):2574-81. PubMed ID: 21606419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.